In Tuesday’s CX Congenital Vascular Malformations session, delegates heard about how approaching congenital vascular malformations with systematic pathways of care and classification systems can greatly assist physicians in achieving consistently successful positive outcomes.
Getinge has announced that, in order to better convey its customer offering and strengthen its position, it has grouped its portfolio under one single brand – Getinge. The company has also now launched the Advanta V12 32mm balloon-expandable covered stent.
Bluegrass Vascular Technologies has enrolled over one third of its patients in the company’s post-market SAVE (Surfacer System to Facilitate Access in Venous Occlusions) clinical study. The SAVE study is an international, prospective, multicentre clinical follow-up study designed to confirm clinical performance and safety of the Surfacer inside-out access catheter system, a device indicated for obtaining central venous access to facilitate catheter insertion into the central venous system in patients with chronically occluded veins.
Ra Medical Systems and bo medical technologies, have announced the launch of the Dabra atherectomy system for cardiovascular and Pharos excimer laser for dermatology in Europe.
PinnacleHealth CardioVascular Institute has enrolled the first US patient in a trial assessing the safety and effectiveness of a new type of approach for blockages in the leg artery.
QXMédical has announced its sponsorship of EVARplanning.com, an online tool which helps vascular and cardiovascular specialists plan complex endovascular aneurysm repair (EVAR) procedures.
Essential Medical has announced the publication of the MANTA CE marking study results in JACC Interventions titled: “Percutaneous plug-based arteriotomy closure device for large-bore access”.
Lombard Medical and MicroPort Scientific Corporation have finalised the definitive agreements to their strategic partnership first announced on 19 December 2016.
iVascular has obtained CE mark for the thrombus extraction catheter Capturer 7F.
Endologix has announced today that the first patients were treated in the ELEVATE (Expanding patient applicability with polymer sealing Ovation Alto stent graft) investigational device exemption (IDE) clinical study, the company’s pivotal clinical trial to evaluate the safety and effectiveness of the Ovation Alto abdominal stent graft system for the repair of infrarenal abdominal aortic aneurysms.
Intact Vascular’s TOBA II (Tack optimized balloon angioplasty II) clinical trial has completed enrolment. A total of 210 patients have been enrolled in TOBA II at 33 sites in the USA and Europe.
The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation.
Updated European Society for Vascular Surgery (ESVS) clinical practice guidelines regarding the management of diseases of the descending thoracic aorta have been published in the European Journal of Vascular and Endovascular Surgery.
The Tsimane people—a forager-horticulturalist population of the Bolivian Amazon—have the lowest reported levels of vascular aging for any population, with coronary atherosclerosis five times less common than in the USA, according to a study published in The Lancet and presented at the American College of Cardiology.
Unfors RaySafe has introduced the RaySafe i3, to its suite of real-time dosimetry products, at the European Society of Radiology in Vienna.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos